Modality
Multispecific
MOA
SGLT2i
Target
AuroraA
Pathway
Cell Cycle
NSCLC
Development Pipeline
Preclinical
Feb 2021
PreclinicalCurrent
NCT06875616
2,250 pts·NSCLC
2021-02→TBD·Recruiting
2,250 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
Preclinical
Recruit…
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06875616 | Preclinical | NSCLC | Recruiting | 2250 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| Motazanubrutinib | Biogen | Preclinical | CD38 | |
| ALN-5628 | Alnylam | Phase 1/2 | APOC3 | |
| ARG-6988 | Argenx | Preclinical | AuroraA |